Clinical Trials
19 trialsNCT03860844 2025-09-09
ISAKIDS
Sanofi
Phase 2 Terminated
NCT04752163 2025-05-23
DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT04095858 2023-02-08
CATHY
Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 3 Terminated
NCT01773395 2022-07-18
GVAX vs. Placebo for MDS/AML After Allo HSCT
Dana-Farber Cancer Institute
Phase 2 Terminated
NCT01187810 2022-03-31
Fenretinide in Children With Recurrent/Resistant ALL, AML, and NHL
South Plains Oncology Consortium
Phase 1 Terminated
NCT01158885 2021-10-26
Clofarabine With Cytarabine for Patients With Minimal Residual Disease Positive Leukemia
Therapeutic Advances in Childhood Leukemia Consortium
Phase 2 Terminated
NCT00003056 2021-05-06
Prevention of Graft-Versus-Host Disease in Patients With Advanced Leukemia or Lymphoma Who Are Eligible for Peripheral Stem Cell Transplantation
Takeda
Phase 3 Terminated
NCT03071276 2020-05-22
Selinexor in Combination With Fludarabine and Cytarabine in Patients With Refractory or Relapsed Acute Myeloid Leukemia
St. Jude Children's Research Hospital
Phase 2 Terminated
NCT02676323 2018-11-14
Panobinostat With Fludarabine and Cytarabine for Treatment of Children With Acute Myeloid Leukemia or Myelodysplastic Syndrome
St. Jude Children's Research Hospital
Phase 1 Terminated
NCT02419755 2018-03-07
Bortezomib and Vorinostat in Younger Patients With Refractory or Relapsed MLL Rearranged Hematologic Malignancies
St. Jude Children's Research Hospital
Phase 2 Terminated
NCT02433483 2017-11-01
Microtransplantation to Treat Refractory or Relapsed Hematologic Malignancies in Younger Patients
St. Jude Children's Research Hospital
Phase 2 Terminated
NCT00281879 2017-09-27
Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer
OHSU Knight Cancer Institute
Phase 2 Terminated
NCT00450983 2017-05-24
Donor Peripheral Stem Cell Transplant and Donor Natural Killer Cell Transplant After Total-Body Irradiation, Thiotepa, Fludarabine, and Muromonab-CD3 in Treating Patients With Leukemia or Other Blood Diseases
Fred Hutchinson Cancer Center
Phase 2 Terminated
NCT00555048 2017-05-24
Alemtuzumab, Busulfan, and Cyclophosphamide Followed By a Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer
Fred Hutchinson Cancer Center
Phase 1/2 Terminated
NCT01118013 2017-03-24
Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Malignancies or Secondary Myelodysplasia Previously Treated With High-Dose Chemotherapy and Autologous Stem Cell Transplant
Alliance for Clinical Trials in Oncology
Phase 2 Terminated
NCT01749111 2017-03-03
CICLODECH
Hospital Israelita Albert Einstein
Phase 3 Terminated
NCT00669890 2015-04-22
High Risk
New York Medical College
Phase 1 Terminated
NCT00005641 2012-12-11
Removal of T Cells to Prevent Graft-Versus-Host Disease in Patients Undergoing Bone Marrow Transplantation
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Terminated
NCT00253552 2012-05-28
G-CSF-Treated Donor Bone Marrow Transplant in Treating Patients With Hematologic Disorders
OHSU Knight Cancer Institute
Phase NA Terminated